Abstract
Intravenous immunoglobulin G preparation (IVIG) is an effective and safe therapeutic modality in the primary immunodeficiencies (PID) management. We investigated effectiveness and safety of the 10% preparation of IVIG Gamunex in treatment of 26 patients with primary immunodeficiencies at ages 8 months 17 years. Percentage of nonsevere reactions to Gamunex infusions was similar as to other 5% IVIG preparations (2,9 vs 2,8%). Average time of infusion was reduced from 88 minutes for 5% IVIG to 67 minutes for Gamunex. Average trough IgG level after Gamunex infusions was sufficient (6,8 g/l) and resulted in the absence of significant infectious episodes in PID patients during the study period. Our study demonstrated good efficacy and safety profile of Gamunex.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
